As of November 1, 2018, the pharmaceutical facility for microbial GMP production in the Netherlands acquired by WACKER with its takeover of SynCo Bio Partners Luxembourg S.à r.l., will be renamed Wacker Biotech B.V. The site in Amsterdam for the manufacture of biopharmaceuticals, live microbial products and vaccines, as well as the associated business, was acquired by WACKER in April 2018.